What question did this study set out to answer?

This research aims to evaluate survival outcomes and identify sensitivity markers for PARP inhibitors in ovarian cancer patients.

April 26, 2026Open Access

Survival Outcomes and Sensitivity of PARP Inhibitors in Platinum‐Sensitive Ovarian Cancer: A Retrospective Study

Key Points

This research aims to evaluate survival outcomes and identify sensitivity markers for PARP inhibitors in ovarian cancer patients.
Conducted a retrospective analysis of Chinese ovarian cancer patients receiving PARP inhibitor maintenance therapy.
Identified biomarkers TFRC and PRNP for predicting PARPi sensitivity.
Over 20% of patients exhibited primary resistance to PARP inhibitors.
TFRC and PRNP are potential biomarkers for assessing PARPi sensitivity, requiring further validation.

Abstract

PARPi maintenance therapy demonstrates substantial clinical benefit in real-world Chinese patients with ovarian cancer. However, over 20% exhibit primary resistance. TFRC and PRNP represent promising biomarkers for predicting PARPi sensitivity and warrant further validation.

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper